Physician profile
Joelle Mast
NPI 1285856054
$1,144.56
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,101 · 2020: $43.10.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Greenwich Biosciences, INC. | $204.85 | 2019 | |
| Sunovion Pharmaceuticals INC. | $175.66 | 2019 | |
| Tris Pharma INC | $122.50 | 2019-2020 | |
| Aquestive Therapeutics, INC. | $115.40 | 2019 | |
| Ironshore Pharmaceuticals INC. | $75.28 | 2019 | |
| Shire North American Group INC | $74.47 | 2019 | |
| Eisai INC. | $69.96 | 2019-2020 | |
| Neos Therapeutics, LP | $60.91 | 2019 | |
| Csl Behring | $47.06 | 2019 | |
| Medtronic USA, INC. | $41.92 | 2019 | |
| Adlon Therapeutics L.P. | $23.61 | 2019 | |
| Biogen, INC. | $23.39 | 2019 | |
| Jazz Pharmaceuticals INC. | $22.53 | 2019 | |
| Novartis Pharmaceuticals Corporation | $21.72 | 2019 | |
| Livanova USA, INC. | $18.08 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $17.41 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.41 | 2019 | |
| Mallinckrodt Enterprises LLC | $12.40 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joelle Mast listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.